Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

Brigitte Autran*, Robert L. Murphy, Dominique Costagliola, Roland Tubiana, Bonaventura Clotet, Jose Gatell, Schlomo Staszewski, Norma Wincker, Lambert Assoumou, Raphaelle El-Habib, Vincent Calvez, Bruce Walker, Christine Katlama

*Corresponding author for this work

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

Objective: Evaluate immunogenicity and clinical efficacy of two immunization strategies with the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients. DESIGN:: Randomized, double-blind, placebo-controlled, phase II study of vCP1452 immunization in chronically HIV-infected patients on therapy with CD4 T-cell count more than 350 cells/μl, CD4 nadir less than 400 cells/μl and pHIV-RNA less than 400 copies/ml. Patients were equally randomized to four injections at weeks 0, 4, 8, 20; three injections at weeks 4, 8, 20; and placebo. The primary endpoint was vaccine immunogenicity at week 24 measured by enzyme-linked immunospot- interferon-γ against the HIV-gag-reverse transcriptase-nef vaccine sequences. Secondary endpoints included time to treatment resumption and viral quantitation following treatment interruption at week 24. Criteria to resume therapy included CD4 T-cell count decline less than 250 cells/μl or 50% decrease from baseline or pHIV-RNA more than 50 000 copies/ml. Results: Sixty-five patients enrolled. Changes from baseline in HIV-specific T cells in the four injection arms (+480 spot-forming cells/M-peripheral blood mononuclear cell) were significant compared to placebo (+8; P ≤ 0.014), but not in the three injection arms (+322). The week 36 pHIV-RNA (log10 copies/ml) after treatment interruption was higher in the four (4.71; P ≤ 0.023) and three (4.82; P ≤ 0.009) injection arms compared to placebo (4.40). Percentages of patients reaching treatment resumption criteria by week 48 were 74, 55 and 23% in the three respective arms (P ≤ 0.013). Two independent factors influenced time to therapy resumption: immunization (hazards ratio ≤ 2.7, P ≤ 0.048 for three injections; hazards ratio ≤ 4.1, P ≤ 0.003 for four injections) and CD4 nadir (hazards ratio ≤ 0.4, P ≤ 0.002). Conclusions: Significant immunogenicity was induced by vCP1452; however, this strategy was independently associated with a shorter time to resume therapy and higher viral rebound.

Original languageEnglish (US)
Pages (from-to)1313-1322
Number of pages10
JournalAIDS
Volume22
Issue number11
DOIs
StatePublished - Jul 11 2008

Keywords

  • Canarypox
  • HIV
  • Therapeutic vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)'. Together they form a unique fingerprint.

  • Cite this

    Autran, B., Murphy, R. L., Costagliola, D., Tubiana, R., Clotet, B., Gatell, J., Staszewski, S., Wincker, N., Assoumou, L., El-Habib, R., Calvez, V., Walker, B., & Katlama, C. (2008). Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS, 22(11), 1313-1322. https://doi.org/10.1097/QAD.0b013e3282fdce94